LICENSE AND COLLABORATIVE ARRANGEMENTS (Details) $ in Thousands		1 Months Ended									3 Months Ended				11 Months Ended	12 Months Ended				54 Months Ended	86 Months Ended
	Oct. 01, 2014 USD ($)	Jun. 30, 2014 USD ($)	Apr. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Aug. 31, 2012 USD ($)	Aug. 31, 2011	Aug. 31, 2010 USD ($)	Nov. 30, 2008 item	Jul. 31, 2008 USD ($)	Jul. 31, 2005 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Mar. 31, 2013 USD ($)	Dec. 31, 2013 item	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2015 USD ($) item	Dec. 31, 2015 USD ($) item
License and collaborative arrangements
Revenue recognized																	$ 31,515	$ 12,796
Royalty revenue																$ 985	1,821	45,003
Mallinckrodt, Inc.
License and collaborative arrangements
Number of products to be developed by utilizing Acuform technology | item								4
Number of products elected to develop | item								2
Upfront fees and milestones payment received																					$ 27,500
Upfront fee received																					4,000
Upfront fee received for formulation work to be performed under the agreement																					$ 1,500
Number of milestone payments received | item																					4
Clinical development milestone payments																					$ 500
Milestone payments following FDA's Acceptance																$ 10,000					$ 5,000
Milestone payment received		$ 5,000	$ 10,000
Milestone revenue recognized				$ 1,000							$ 5,000	$ 10,000
Janssen Pharmaceutica N.V.
License and collaborative arrangements
Upfront fee received					$ 10,000		$ 10,000
Milestone payment received							$ 10,000
Number of projects completed | item															2
Revenue recognized													$ 1,400	$ 2,200
Ironwood Pharmaceuticals, Inc.
License and collaborative arrangements
Upfront fees, initial product formulation work and milestone payments received																				$ 3,400
Number of milestone payments received | item																				3
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) | Commercialization Agreement
License and collaborative arrangements
Revenue recognized																	3,000	1,400	$ 3,300
Royalties on net product sales, percentage in 2011						26.50%
Royalties on net product sales, percentage in 2012						29.50%
Royalties on net product sales, percentage in 2013 and 2014						32.00%
Royalties on net product sales, percentage in 2015 and beyond						34.50%
Royalty revenue																		42,100	42,800
Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) | Promotion Agreement
License and collaborative arrangements
Upfront fee received									$ 12,000
Revenue recognized	$ 1,900
Valeant Pharmaceuticals International, Inc.
License and collaborative arrangements
Upfront fee received										$ 25,000
Revenue recognized																	$ 12,500	$ 1,600	$ 1,600
Valeant Pharmaceuticals International, Inc. | 1000mg Glumetza
License and collaborative arrangements
Revenue recognized	$ 11,300